Human Genome Epidemiology Literature Finder
|
Records 1 - 21 (of 21 Records) |
| Query Trace: Breast Neoplasms and MUT[original query] |
|---|
| Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study. International journal of cancer. Journal international du cancer 2003 Sep 106 (4): 588-93. de Sanjosé Silvia, Léoné Mélanie, Bérez Victoria, Izquierdo Angel, Font Rebeca, Brunet Joan M, Louat Thierry, Vilardell Loreto, Borras Joan, Viladiu Pau, Bosch F Xavier, Lenoir Gilbert M, Sinilnikova Olga |
| Dose and polymorphic genes xrcc1, xrcc3, gst play a role in the risk of articledeveloping erythema in breast cancer patients following single shot partial breast irradiation after conservative surgery. BMC cancer 2011 11 (1): 291. Falvo Elisabetta, Strigari Lidia, Citro Gennaro, Giordano Carolina, Arcangeli Stefano, Soriani Antonella, D'Alessio Daniela, Muti Paola, Blandino Giovanni, Sperduti Isabella, Pinnarò Pao |
| Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2015 May 26 (5): 914-20. Monk B J, Ghatage P, Parekh T, Henitz E, Knoblauch R, Matos-Pita A S, Nieto A, Park Y C, Cheng P S, Li W, Favis R, Ricci D, Poveda |
| Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Bone marrow transplantation 2016 Apr . Boudin L, Gonçalves A, Sabatier R, Moretta J, Sfumato P, Asseeva P, Livon D, Bertucci F, Extra J-M, Tarpin C, Houvenaegel G, Lambaudie E, Tallet A, Resbeut M, Sobol H, Charafe-Jauffret E, Calmels B, Lemarie C, Boher J-M, Viens P, Eisinger F, Chabannon |
| Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature. Breast cancer research and treatment 2017 8 166 (2): 339-349. Petrelli Fausto, Tomasello Gianluca, Barni Sandro, Lonati Veronica, Passalacqua Rodolfo, Ghidini Miche |
| Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients. Journal of the American College of Surgeons 2018 1 226 (4): 560-565. Pederson Holly J, Gopalakrishnan Dharmesh, Noss Ryan, Yanda Courtney, Eng Charis, Grobmyer Stephen |
| EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer. Future oncology (London, England) 2019 8 15 (28): 3209-3218. Bardia Aditya, Aftimos Philippe, Bihani Teeru, Anderson-Villaluz Alfred T, Jung JungAh, Conlan Maureen G, Kaklamani Virginia |
| Protein interaction disruption in cancer. BMC cancer 2019 Apr 19 (1): 370. Ruffalo Matthew, Bar-Joseph Z |
| Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 Jun . Sun Xiangjie, Zuo Ke, Yao Qianlan, Zhou Shuling, Shui Ruohong, Xu Xiaoli, Bi Rui, Yu Baohua, Cheng Yufan, Tu Xiaoyu, Lu Hongfen, Yang Went |
| Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature. Journal of the National Comprehensive Cancer Network : JNCCN 2020 5 18 (5): 517-521. Chumsri Saranya, Sokol Ethan S, Soyano-Muller Aixa E, Parrondo Ricardo D, Reynolds Gina A, Nassar Aziza, Thompson E Aubr |
| Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Annals of oncology : official journal of the European Society for Medical Oncology 2020 May . Karn T, Denkert C, Weber K E, Holtrich U, Hanusch C, Sinn B V, Higgs B W, Jank P, Sinn H P, Huober J, Becker C, Blohmer J-U, Marmé F, Schmitt W D, Wu S, van Mackelenbergh M, Müller V, Schem C, Stickeler E, Fasching P A, Jackisch C, Untch M, Schneeweiss A, Loibl |
| Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast cancer research : BCR 2020 May 22 (1): 45. Martínez-Sáez Olga, Chic Nuria, Pascual Tomás, Adamo Barbara, Vidal Maria, González-Farré Blanca, Sanfeliu Esther, Schettini Francesco, Conte Benedetta, Brasó-Maristany Fara, Rodríguez Adela, Martínez Débora, Galván Patricia, Rodríguez Ana Belén, Martinez Antonio, Muñoz Montserrat, Prat Ale |
| Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology 2020 Mar 31 (3): 387-394. Barroso-Sousa R, Jain E, Cohen O, Kim D, Buendia-Buendia J, Winer E, Lin N, Tolaney S M, Wagle |
| Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. Hepatology (Baltimore, Md.) 2021 3 74 (3): 1429-1444. Boerner Thomas, Drill Esther, Pak Linda M, Nguyen Bastien, Sigel Carlie S, Doussot Alexandre, Shin Paul, Goldman Debra A, Gonen Mithat, Allen Peter J, Balachandran Vinod P, Cercek Andrea, Harding James, Solit David B, Schultz Nikolaus, Kundra Ritika, Walch Henry, D'Angelica Michael I, DeMatteo Ronald P, Drebin Jeffrey, Kemeny Nancy E, Kingham T Peter, Simpson Amber L, Hechtman Jaclyn F, Vakiani Efsevia, Lowery Maeve A, Ijzermans J N M, Buettner S, Koerkamp B Groot, Doukas M, Chandwani Rohit, Jarnagin William |
| Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients. Cancer medicine 2022 4 11 (14): 2767-2778. Liu Binliang, Yi Zongbi, Guan Yanfang, Ouyang Quchang, Li Chunxiao, Guan Xiuwen, Lv Dan, Li Lixi, Zhai Jingtong, Qian Haili, Xu Binghe, Ma Fei, Zeng Yix |
| Molecular profiles and circulating tumor-DNA detected in Chinese early stage breast cancer. Gland surgery 2022 3 11 (2): 319-329. Lan Jing, Zhou Ye-Hui, Zhang Min-Xia, Chen Dong-Qin, Wu Meng-Yao, Yu Zheng-Yu |
| PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer. NPJ breast cancer 2022 Feb 8 (1): 24. Migliaccio Ilenia, Paoli Marta, Risi Emanuela, Biagioni Chiara, Biganzoli Laura, Benelli Matteo, Malorni Lu |
| Clinical and Genomic Characteristics of Patients with HR+, HER2- Metastatic Breast Cancer Following Progression on a CDK4 and 6 Inhibitor. Clinical cancer research : an official journal of the American Association for Cancer Research 2023 6 . Xi Rao, Yongmei Chen, Julie Beyrer, Emily Nash Smyth, Claudia Morato Guimaraes, Lacey M Litchfield, Lee Bowman, Garreth W Lawrence, Amit Aggarwal, Fabrice And |
| Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers. Genome medicine 2023 4 15 (1): 28. Katherine E Hutchinson, Jessica W Chen, Heidi M Savage, Thomas J Stout, Frauke Schimmoller, Javier Cortés, Susan Dent, Nadia Harbeck, William Jacot, Ian Krop, Sally E Trabucco, Smruthy Sivakumar, Ethan S Sokol, Timothy R Wils |
| Molecular profiling of male breast cancer by multigene panel testing: Implications for precision oncology. Frontiers in oncology 2023 1 12 1092201. Valentini Virginia, Silvestri Valentina, Bucalo Agostino, Conti Giulia, Karimi Mina, Di Francesco Linda, Pomati Giulia, Mezi Silvia, Cerbelli Bruna, Pignataro Maria Gemma, Nicolussi Arianna, Coppa Anna, D'Amati Giulia, Giannini Giuseppe, Ottini Lau |
| The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab. ESMO open 2024 5 9 (5): 102964. L Buisseret, Y Bareche, D Venet, E Girard, A Gombos, P Emonts, S Majjaj, G Rouas, M Serra, V Debien, E Agostinetto, S Garaud, K Willard-Gallo, D Larsimont, J Stagg, F Rothé, C Sotiri |
- Page last reviewed:Feb 1, 2024
- Content source: